127 related articles for article (PubMed ID: 8291452)
1. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease.
Szilágyi A; Hole R; Keckstein J; Rossmanith WG
Gynecol Endocrinol; 1993 Sep; 7(3):159-66. PubMed ID: 8291452
[TBL] [Abstract][Full Text] [Related]
2. Impairment of dopaminergic and opioidergic activity in patients with polycystic ovarian disease is restored by treatment for the induction of ovulation.
Nappi C; Petraglia F; Di Carlo C; De Rosa R; Zaccardo A; Genazzani AR; Montemagno U
Gynecol Obstet Invest; 1989; 27(1):38-41. PubMed ID: 2920972
[TBL] [Abstract][Full Text] [Related]
3. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
4. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
[TBL] [Abstract][Full Text] [Related]
5. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
Judd HL; Rigg LA; Anderson DC; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
[TBL] [Abstract][Full Text] [Related]
7. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome.
Cumming DC; Reid RL; Quigley ME; Rebar RW; Yen SS
Clin Endocrinol (Oxf); 1984 Jun; 20(6):643-8. PubMed ID: 6088126
[TBL] [Abstract][Full Text] [Related]
8. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
[TBL] [Abstract][Full Text] [Related]
9. Effect of antagonists of dopamine and opiates on the basal and GnRH-induced secretion of luteinizing hormone, follicle stimulating hormone and prolactin during lactational amenorrhoea in breastfeeding women.
Tay CC; Glasier AF; McNeilly AS
Hum Reprod; 1993 Apr; 8(4):532-9. PubMed ID: 8501180
[TBL] [Abstract][Full Text] [Related]
10. Acute dopaminergic blockade augments the naloxone-induced LH rise in estrogen-treated postmenopausal women.
Parra A; Barrón J; Marín VA; Coutiño B; Belmont J; Coria I
Maturitas; 1997 May; 27(1):91-9. PubMed ID: 9158083
[TBL] [Abstract][Full Text] [Related]
11. Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in the control of prolactin, growth hormone and gonadotropin secretion in prepubertal rats.
González LC; Pinilla L; Tena-Sempere M; Aguilar E
J Endocrinol; 1999 Sep; 162(3):417-24. PubMed ID: 10467233
[TBL] [Abstract][Full Text] [Related]
12. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
13. Is opioidergic activity responsible for the circadian variation observed in the gonadotrophin responsiveness of early follicular phase women?
Rossmanith WG; Grasshof C
Clin Endocrinol (Oxf); 1998 Oct; 49(4):499-503. PubMed ID: 9876348
[TBL] [Abstract][Full Text] [Related]
14. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
Barletta C; Vagiri D; Scavo D
Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
[TBL] [Abstract][Full Text] [Related]
15. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
Barnes RB; Lobo RA
J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
[TBL] [Abstract][Full Text] [Related]
16. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion.
Yen SS; Quigley ME; Reid RL; Ropert JF; Cetel NS
Am J Obstet Gynecol; 1985 Jun; 152(4):485-93. PubMed ID: 2990210
[TBL] [Abstract][Full Text] [Related]
18. The impact of ovarian laser surgery on the gonadotrophin secretion in women with polycystic ovarian disease.
Rossmanith WG; Keckstein J; Spatzier K; Lauritzen C
Clin Endocrinol (Oxf); 1991 Mar; 34(3):223-30. PubMed ID: 1903681
[TBL] [Abstract][Full Text] [Related]
19. The acute effects of a dopamine antagonist (domperidone) on luteinising hormone, follicule stimulating hormone, prolactin and thyrotrophin secretion in polycystic ovarian syndrome: differential effect of ovulation.
Murdoch AP; Dunlop W; Kendall-Taylor P; Watson MJ
Clin Endocrinol (Oxf); 1984 Dec; 21(6):611-9. PubMed ID: 6439439
[TBL] [Abstract][Full Text] [Related]
20. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
